Pixium Vision selected to participate in the French side of health program organized by Business France and Bpifrance, by strengthening the presence in the United States
Paris, June 19, 2020 – 07.30 hrs (CET) – Pixium Vision (Euronext Croissance de Paris – FR0011950641), an innovative bioelectronics company that develops bionic vision systems to allow patients who have lost their sight to live more independently, announces today that it is one of the 13 laureates selected from among the most innovative in French lifescience companies to take part in an investor roadshow in October 2020, organized by Business France and Bpifrance.
Pixium Vision will update investors on its plans for the bionic vision Prima System and increase awareness in the United States of its exciting development and business plans. Recent 18-month data showed Prima System is able to combine natural residual vision with central vision prostheses in patients with age-related macular degeneration (AMD), paving the way for pivotal study .
Pixium Vision is currently carrying out feasibility studies for the Prima System in France and the US and is continuing preparations for the PRIMAvera pivotal study, which should begin no later than 2020, that is in the first half of 2021. The US the feasibility study should resume as soon as COVID-19 situation allows.
“The clinical development of the Prima System is progressing rapidly in Europe and in the United States and the Next French Health care program is an ideal opportunity to increase Pixium Vision’s presence in the United States and the update that drives US potential investors and partners on our plans. Pixium Vision is ready for the next steps of the current transition, based on a full-fledged research of the commercial organization, both in Europe and in the United States ” said Lloyd Diamond, CEO of Pixium Vision.
Chief Financial Officer
+33 1 76 21 47 68
|Media relations |
Guillaume van Renterghem
+33 6 69 99 37 83
Pixium Vision is to create a world of bionic vision for those who have lost their sight, allowing them to regain visual perception and greater autonomy. Pixium Vision bionic vision systems are associated with surgery and a period of rehabilitation. Prima Miniature Wireless Photovoltaic Subretinal System Implant is in clinical trials for patients who have lost their sight due to external retinal degeneration, first for age-related dry atrophic macular degeneration (AMD). dry type). Pixium Vision collaborates closely with academic and research partner institutions, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Vision Institute in Paris, Moorfields Eye Hospital London, Institute of Eye Microsurgery (OMI), Barcelona, University Hospital Bonn, and UPMC, Pittsburgh, PA. The company is EN ISO 13485 and qualifies them as “Innovative Company” by Bpifrance.
For more information: http://www.pixium-vision.com/fr
Follow us on @PixiumVision; www.facebook.com/pixiumvision www.linkedin.com/company/pixium-vision
2020-06-19 – FRA Final SA Pixium_USRoadshow docx